Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus dexamethasone for newly diagnosed POEMS syndrome
ChiCTR2200056637Phase 4Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pomalidomide and dexamethasone in osteosclerotic myeloma (POEMS), sponsored by Qingdao Municipal Hospital. Primary endpoints: Progression-free survival, Neurological response and 2 more. Started Dec 2021; status: recruiting.
02
Drugs
pomalidomidedexamethasone
03
Conditions
osteosclerotic myeloma (POEMS)
Beyond the preview
Go deeper on ChiCTR2200056637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056637.